MANEVeradermics, Incorporated
Price
End-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for MANE today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a dermatologist-founded, late clinical-stage biopharmaceutical company, or the “Company,” “we,” “us,” or “our”, focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for PHL, a condition affecting approximately 50 million men and 30 million women in the United States.
In the company’s own words · 10-K filed Mar 30, 2026 · SEC EDGAR
The next results filing is expected around Nov 10, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 19, 2026On October 19, 2026, the Company announced positive topline data from the Phase 3 clinical trial, Study ‘304’ evaluating VDPHL01 in males with mild-to-moderate pattern hair loss.Regulation FD disclosure · Form 8-K
- Aug 11, 2026Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.Earnings release · press release
- Jul 15, 2026On July 15, 2026, the Company announced positive topline results from Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry